Abzena partners with FDA on publication demonstrating the benefits of the MAPPs assay for immunogenicity

SAN DIEGO, Dec. 19, 2023 /PRNewswire/ — Abzena, the leading end-to-end CDMO for complex biologics and bioconjugates, has co-authored a publication with the US Food and Drug Administration (FDA) demonstrating the potential of the MHC Associated Peptide Proteomics (MAPPs) assay as an…

Click here to view original post